Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0527/2021

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0527/2021

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0172/2021

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0172/2021

Opinion/decision on a Paediatric investigation plan (PIP): Translarna, Ataluren, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0196/2023

Opinion/decision on a Paediatric investigation plan (PIP): Translarna, Ataluren, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0196/2023

Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta, Ceftazidime,Avibactam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0551/2022

Opinion/decision on a Paediatric investigation plan (PIP): Zavicefta, Ceftazidime,Avibactam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0551/2022

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0469/2020

Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0469/2020

Opinion/decision on a Paediatric investigation plan (PIP): Cerdelga, Eliglustat (tartrate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0440/2022

Opinion/decision on a Paediatric investigation plan (PIP): Cerdelga, Eliglustat (tartrate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0440/2022

Opinion/decision on a Paediatric investigation plan (PIP): Livmarli, Maralixibat chloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0488/2023

Opinion/decision on a Paediatric investigation plan (PIP): Livmarli, Maralixibat chloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0488/2023

Opinion/decision on a Paediatric investigation plan (PIP): Veklury, remdesivir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0439/2023

Opinion/decision on a Paediatric investigation plan (PIP): Veklury, remdesivir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0439/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness